Comparison between latanoprost and brimonidine efficacy and safety in Indian eyes

Indian Journal of Ophthalmology

Volumn 51, Issue 2, 2003, Pages 123-128

  Thomas, Ravi ^a   Parikh, Rajul ^b   Muliyil, Jayaprakash ^b   George, Ronnie ^b   Paul, Padma ^b   Abraham, Lekha M ^b  

^a L V PRASAD EYE INSTITUTE   (India)

^b Christian Medical College Hospital   (India)

Author keywords

Brimonidine; Efficacy; Glaucoma; Intraocular pressure reduction; Latanoprost; Safety

Indexed keywords

BRIMONIDINE; LATANOPROST;

ADULT; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLAUCOMA; HUMAN; HYPERTRICHOSIS; INDIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIS DISEASE; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; OUTCOMES RESEARCH; PSEUDOEXFOLIATION; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC ALPHA-AGONISTS; ADULT; EXFOLIATION SYNDROME; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC; QUINOXALINES; TREATMENT OUTCOME;

EID: 0038408561     PISSN: 03014738     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Wilson RM. Epidemiology of chronic open angle glaucoma. In:Ritch R, Sheilds B, Krupin T, editors. The Glaucomas, 2nd ed. St. Louis: Mosby Year Book, 1996. Vol 2, pp 758-68.
2. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998;126:498-505.
3. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000;130:429-40.
4. Diggory P, Heyworth P, Chau G, McKenzie S, Sharma A, Luke I. Improved lung function tests on changing from topical timolol. Non-selective beta-blockade impairs the lung function tests in elderly patients. Eye 1993;7:661-67.
5. Avorn J, Glynn R, Gurwitz JH, Bohn RL, Mamane M, Everilt DE. Pulmonary effects of beta-blockers. J Glaucoma 1993;2:158-65.
6. Camras CB. Prostaglandins. In: Ritch R, Shields MB, Krupin T, editors. The Glaucomas, 2nd ed. St. Louis: Mosby-Year Book, 1996. Vol 2, pp 1449-61.
7. Alm A, Villumsen J. Ph XA34, a new potent ocular hyporensive drug, A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. Arch Ophthalmol 1991;109:1564-68.
8. Villumsen J, Alm A. Ph XA34, a prostagndins F2a analogue effect on intraocular pressure in patients with ocular hypertension. Br J Ophthalmol 1992;76:214-17.
9. Camras CB, Schumer RA, Marks A et al. Intraocular pressure reduction with Ph XA34, a new prostaglandins analogue, in patients with ocular hypertensions. Arch Ophthalmol 1992;110:1733-38.
10. Stjernschantz J, Alm A. Latanoprost as a new horizon in the medical management of glaucoma. Curr Opin Ophthalmol 1996;7:11-17.
11. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 1996;103:138-47.
12. Watson PG, The Latanoprost Study group. Latanoprost: Two years' experience of its use in United Kingdom. Ophthalmology 1998;05:82-87.
13. Alm A, Widengard, Latanoprost: Experience of 2-year treatment in Scandinavia. Archives of Ophthalmology Scandinavia. 2000;78:71-76.
14. Azuara-Blanco A, Katz LJ, Spaeth GL, Wilson RP, Moster MR, Flartey KJ. Effect of latanoprost on intraocular pressure in patients with glaucoma on maximal tolerated medical treatment. Br J Ophthalmol 1997;81:1116.
15. Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol 1996;114:929-32.
16. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol 1999;128:8-14.
17. Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K. A controlled randomized, Multicentric Clinical Trial, A 1 year study of Brimonidine twice daily in Glaucoma and Ocular Hypertension. Arch Ophthalmol 1997;115:847-52.
18. Stewart WC, Day DG, Stewart JA, Schuhr J, Latham KE. The efficacy and safety of Latanoprost 0.005% Once a daily Versus Brimonidine 0.2% Twice daily in a Open-Angle Glaucoma or Ocular Hypertension. Am J Ophthalmol 2001;131:631-35.
19. Rao PSSS, Richard J. An Introduction to Biostatistics. 3rd ed. Mumbai: Prentice-Hall of India. pp. 70-75.
20. Katz LJ, The Brimonidine study group. Brimonidine tartrate 0.2 % twice daily VS Timolol 0.5 % twice daily. 1 year results in glaucoma patients. Am J Ophthalmol 1999;127:20-26.
21. Leblanc RP. The Brimonidine study group. Twelve-month results of an ongoing randomized, trial comparing Brimonidine tartrate 0.2 % and Timolol 0.5 % given twice daily with Glaucoma and ocular hypertension. Ophthalmology 1998;105:1960-67.
22. Serle JB. The Brimonidine study group III. A comparison of safety and efficacy twice-daily Brimonidine 0.2 % VS betoxolol 0.25 % in subjects with elevated intraocular pressure. Survey of Ophthalmology 1996;41:S39-S47.
23. Walters DR. development and use of Brimonidine in treating acute and chronic elevation of intra ocular pressure. A review of safety, efficacy and dosing studies. Survey of Ophthalmology 41; 1996: S19-S26.
24. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhxA 41, a new prostaglandins F2a analogue, after topical application in normal and ocular hypertensive eyes. Am J Ophthalmol 1993;111:1351-58.
25. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intra ocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000;2:134-42.
26. Derick RJ, Robin AL, Walters TR, Barnebey HS, Choplin N, Schuman J, et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology 1997;104:131-36.
27. Nordland JR, Pasquale LR, Robin AL, Rudikoff MT, Ordman J, Chen KS, et al. The cardiovascular, Pulmonary and ocular hypotensive effecys of 0.2 % Brimonidine: Arch Ophthalmol 1995;113:77-83.
28. Walters DR. development and use of Brimonidine in treating acute and chronic elevation of intra ocular pressure. A review of safety, efficacy and dosing studies. Survey of Ophthalmology 41;1996:S19-S26